Drug racing to $1 billion on PBS

MSD's monoclonal antibody Keytruda is off to a cracker start for 2025, as the drug solidifies its place at the top of the earnings table.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here